Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Mark J Mitton-FryDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.ORCID 0000-0002-6715-8836
Jason E CummingsDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Yanran LuDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
Jillian F ArmeniaDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Jo Ann W BylDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Alexandria A OviattDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.ORCID 0000-0002-4629-7642
Allison A BaumanDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Gregory T RobertsonDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Neil OsheroffDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.ORCID 0000-0002-2550-4884
Richard A SlaydenDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Funding
TASK ORDER 5: MAKE READY THE NIH BABY TOOLBOX FOR END USERS: FINALIZE ALL PARTICIPANT-LEVEL DATA COLLECTION, ANALYSES, AND DISSEMINATION75N94019D00005 · NICHD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GERSHON, RICHARD · 2019 to 2024
$12.7M
BIOCHEMICAL &CHEMICAL TRAINING FOR CANCER RESEARCHT32CA009582 · NCI · VANDERBILT UNIVERSITY · PI David K Cortez · 1987 to 2026
$8.8M
Chemical Biology of Infectious Diseases (CBID) Training ProgramT32AI112541 · NIAID · VANDERBILT UNIVERSITY · PI Eric P Skaar · 2015 to 2026
$4.0M
Mechanistic Studies of Gyrase/Topoisomerase IV-Targeted AntibacterialsR01AI170546 · NIAID · VANDERBILT UNIVERSITY · PI NEIL OSHEROFF · 2023 to 2026
$2.7M
Mechanistic Studies of Type II Topoisomerases and Topoisomerase-Targeted AgentsR01GM126363 · NIGMS · VANDERBILT UNIVERSITY · PI OSHEROFF, NEIL · 2018 to 2025
$2.6M
Overcoming Resistance to Novel Bacterial Topoisomerase InhibitorsR01AI173072 · NIAID · OHIO STATE UNIVERSITY · PI Mark J. Mitton-Fry · 2023 to 2026
$2.4M
Overcoming fluoroquinolone resistance in Neisseria gonorrhoeaeF31AI149863 · NIAID · VANDERBILT UNIVERSITY · PI OVIATT, ALEXANDRIA · 2020 to 2021
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Anti-Mycobacterial Activity of Bacterial Topoisomerase Inhibitors with Dioxygenated Linkers. · full record | OpenQuestion